FORMA Therapeutics, Inc.

131 articles about FORMA Therapeutics, Inc.

• Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/12/2021

  Forma Therapeutics Holdings, Inc. today reported financial results for the third quarter ended Sept. 30, 2021.

• Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021

  11/5/2021

  Forma Therapeutics Holdings, Inc. today announced that it will release third quarter 2021 financial results Friday, Nov. 12, 2021.

• Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting

  11/4/2021

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, announced that four abstracts have been accepted for presentation – including three oral presentations and one poster presentation – at the 63rd American Society of Hematology Annual Meeting taking place Dec. 11-14, 2021.

• Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer

  10/7/2021

  Initial eight patients treated in ongoing first-in-human, open-label, dose-finding trial of CBP/p300 inhibitor in late-line mCRPC patients

• Forma Therapeutics to Participate in Upcoming Investor Conferences - Sep 17, 2021

  9/17/2021

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that company management will participate in two upcoming investor conferences.

• Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/13/2021

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, reported financial results for the second quarter ended June 30, 2021.

• Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021

  8/6/2021

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021.

• 

  Clinical Catch-Up: June 14-18

  6/21/2021

  It was another busy week of clinical trial announcements. Here’s a look.

• Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer

  6/14/2021

  Forma Therapeutics Holdings, Inc. today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer.

• Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress

  6/11/2021

  Forma Therapeutics Holdings, Inc. a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced new data from its ongoing Phase 1 trial of etavopivat being presented at the 26th Annual European Hematology Association 2021 Virtual Congress.

• Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

  5/20/2021

  Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in people living with R/R AML with the IDH1 mutation Among those with CR/CRh, estimated 18-month survival is 87%; median overall survival has not yet been reached Duration of response of 13.8 months is longest reported in this treatment setting to date

• Forma Therapeutics to Participate in Upcoming Investor Conferences - May 17, 2021

  5/17/2021

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that company management will participate in two upcoming investor conferences

• Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

  5/6/2021

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release first quarter 2021 financial results on Friday, May 14, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on May 14, 2021, to discuss these financial results and provide a business update.

• Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update

  3/30/2021

  Strong organizational foundation laid in 2020; continued pipeline execution amid COVID-19 and raised gross capital of $595.1 million Key 2020 pipeline achievements include proof of concept for FT-4202 in sickle cell disease; successful interim analysis of registrational Phase 2 trial of olutasidenib in R/R AML with IDH1m; and commencement of Phase 1 trial for FT-7051 in mCRPC

• Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study

  3/30/2021

  Blinded data from the 600 mg dose cohort support the doses (400 mg v 200 mg v placebo) being evaluated in the Hibiscus Study currently enrolling people living with sickle cell disease (SCD) Doubling the dose of FT-4202 to 600 mg daily for 14 days compared to the previous 300 mg cohort was well-tolerated with no dose-limiting toxicities or treatment-related adverse events observed

• Forma Therapeutics to Participate in Upcoming Investor Conferences - Feb 17, 2021

  2/17/2021

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that company management will participate in three upcoming investor conferences

• Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones

  1/11/2021

  Strong pipeline progress in 2020 positions company well for 2021 Established proof of concept in SCD for FT-4202 Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants Completed successful IPO and follow-on equity offering

• Forma Therapeutics Announces Pricing of Public Offering - Dec 11, 2020

  12/11/2020

  Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock at a public offering price of $45.25 per share.

• Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/12/2020

  Strong pipeline progress amid challenging COVID-19 environment Oral presentation of MAD1 results at upcoming 2020 ASH Virtual Annual Meeting from the randomized, placebo-controlled multi-center Phase 1 trial evaluating FT-4202 in people with sickle cell disease MAD2 cohort of the Phase 1 trial now enrolling with 600 mg dose

• Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

  11/10/2020

  Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). FT-4202 was previously